Literature DB >> 7587775

Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection.

E D'Amico1, M Paroli, V Fratelli, C Palazzi, V Barnaba, F Callea, G Consoli.   

Abstract

Interferon-alpha is known to exacerbate and in some cases induce a variety of autoimmune disorders. In this report we describe the onset of primary biliary cirrhosis in a 55-year-old woman without evidence of preexisting autoimmune diseases receiving recombinant interferon-alpha 2a for chronic active hepatitis C. Shortly after discontinuing interferon therapy, alkaline phosphatase levels started to rise up to three times the normal range. Anti-mitochondrial antibodies were found to be positive at a high titer, and liver biopsy showed a picture of chronic active hepatitis along with primary biliary cirrhosis features (overlap syndrome). Primary biliary cirrhosis should be considered in the differential diagnosis in any patient treated with interferon-alpha with unexplained elevation of serum alkaline phosphatase.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7587775     DOI: 10.1007/BF02208992

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  18 in total

1.  HCV and Sjögren's syndrome.

Authors:  A Aceti; G Taliani; M Sorice; M A Amendolea
Journal:  Lancet       Date:  1992-06-06       Impact factor: 79.321

2.  Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis.

Authors:  P Fabris; C Betterle; A Floreani; N A Greggio; F de Lazzari; R Naccarato; M Chiaramonte
Journal:  Lancet       Date:  1992-08-29       Impact factor: 79.321

3.  Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors.

Authors:  L E Rönnblom; G V Alm; K E Oberg
Journal:  Ann Intern Med       Date:  1991-08-01       Impact factor: 25.391

4.  Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.

Authors:  W J Mayet; G Hess; G Gerken; S Rossol; R Voth; M Manns; K H Meyer zum Büschenfelde
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

5.  Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial.

Authors:  G L Davis; L A Balart; E R Schiff; K Lindsay; H C Bodenheimer; R P Perrillo; W Carey; I M Jacobson; J Payne; J L Dienstag
Journal:  N Engl J Med       Date:  1989-11-30       Impact factor: 91.245

6.  Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process.

Authors:  S Mishiro; Y Hoshi; K Takeda; A Yoshikawa; T Gotanda; K Takahashi; Y Akahane; H Yoshizawa; H Okamoto; F Tsuda
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

7.  Hepatitis C viraemia in adults with type 2 autoimmune hepatitis.

Authors:  J A Garson; M Lenzi; C Ring; F Cassani; G Ballardini; M Briggs; R S Tedder; F B Bianchi
Journal:  J Med Virol       Date:  1991-08       Impact factor: 2.327

8.  Modulation of expression of MHC antigens in the kidneys of mice by murine interferon-alpha/beta.

Authors:  J E Maguire; I Gresser; A H Williams; G L Kielpinski; R B Colvin
Journal:  Transplantation       Date:  1990-01       Impact factor: 4.939

9.  Selective expansion of cytotoxic T lymphocytes with a CD4+CD56+ surface phenotype and a T helper type 1 profile of cytokine secretion in the liver of patients chronically infected with Hepatitis B virus.

Authors:  V Barnaba; A Franco; M Paroli; R Benvenuto; G De Petrillo; V L Burgio; I Santilio; C Balsano; M S Bonavita; G Cappelli
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

10.  Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

Authors:  I G McFarlane; H M Smith; P J Johnson; G P Bray; D Vergani; R Williams
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

View more
  6 in total

1.  Erythromycin-induced primary biliary cirrhosis.

Authors:  D A Lazarczyk; M C Duffy
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

2.  Primary biliary cholangitis triggered by DAAs-induced HCV clearance: a biological proof of concept.

Authors:  Maria Rendina; Nicola Maurizio Castellaneta; Giuseppe Losurdo; Antonino Castellaneta; Annamaria Cazzolla; Claudia Chialà; Francesca D'Errico; Alfredo Di Leo
Journal:  Ther Adv Chronic Dis       Date:  2018-02-12       Impact factor: 5.091

Review 3.  Interferon alpha: The key trigger of type 1 diabetes.

Authors:  Angela Lombardi; Effie Tsomos; Sara S Hammerstad; Yaron Tomer
Journal:  J Autoimmun       Date:  2018-08-14       Impact factor: 7.094

Review 4.  Cytokine-induced autoimmune disorders.

Authors:  P Miossec
Journal:  Drug Saf       Date:  1997-08       Impact factor: 5.606

5.  Chronic hepatitis C and autoimmune cholangitis: a case study and literature review.

Authors:  Pilar Sánchez-Pobre; Carmen Gonzalez; Estela Paz; Francisco Colina; Gregorio Castellano; Teresa Muñoz-Yague; Sarbelio Rodriguez; Carmen Yela; Victoria Alvarez; Ja Solís-Herruzo
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

6.  Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Authors:  Tatsuo Kanda; Shin Yasui; Masato Nakamura; Shingo Nakamoto; Koji Takahashi; Shuang Wu; Reina Sasaki; Yuki Haga; Sadahisa Ogasawara; Tomoko Saito; Kazufumi Kobayashi; Soichiro Kiyono; Yoshihiko Ooka; Eiichiro Suzuki; Tetsuhiro Chiba; Hitoshi Maruyama; Fumio Imazeki; Mitsuhiko Moriyama; Naoya Kato
Journal:  Oncotarget       Date:  2018-02-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.